Flaxseed, an edible seed that is rich in omega 3-fatty acids and fiber-related compounds known as lignans, is effective in halting prostate tumor growth, according to a study led by Duke University Medical Center researchers.
North Central Cancer Treatment Group researchers, based at Mayo Clinic in Rochester, Minn., have generated preliminary data suggesting that a form of American ginseng provides greater improvements in fatigue and vitality in patients who receive the highest doses tested, compared to lower doses or no treatment.
Enzastaurin, an investigational targeted, oral agent under development by Eli Lilly and Company, showed encouraging results in treating patients with late-stage non-small cell lung cancer (NSCLC), according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
In the first scientific study of its kind, shark cartilage extract, AE-941 or Neovastat, has shown no benefit as a therapeutic agent when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer, according to researchers at the University of Texas M. D. Anderson Cancer Center.
Last year, a groundbreaking international project found that a group of Japanese patients with advanced non-small cell lung cancer survived longer ?and had a higher rate of side effects ? than U.S. patients with the same diagnosis,.when both groups were given two well-known drugs for the disease.
Oregon Health & Science University Cancer Institute researchers have identified a protein that is a strong indicator of survival for men with advanced prostate cancer.
Researchers at Eli Lilly and Company are actively investigating the efficacy and safety of lung cancer treatments ALIMTA (pemetrexed for injection) and GEMZAR (gemcitabine HCl for injection) in treating non-small cell lung cancer in African-Americans, Hispanics and other diverse populations.
Women with breast cancer who receive higher doses of radiation with IMRT each day can reduce their treatment time by two weeks without increasing side effects, according to a study released today in the June 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.
CIGNA HealthCare is teaming up with the non-profit organization HopeLab to deliver innovative interventions that improve the health and quality of life of young people with chronic illnesses.
Cancer survivors may be considered by many as ?the lucky ones?, but new research reveals that many continue to struggle with physical, emotional and psychological problems well after the disease has left them.